Literature DB >> 17487534

Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene.

Larissa Wakefield1, Hilary Long, Nathan Lack, Edith Sim.   

Abstract

The xenobiotic metabolizing enzyme, mouse arylamine N-acetyltransferase type 2 (Nat2), is expressed during embryogenesis from the blastocyst stage and in the developing neural tube and eye. Mouse Nat2 is widely believed to have an endogenous role distinct from xenobiotic metabolism, and polymorphisms in the human ortholog have been implicated in susceptibility to spina bifida and orofacial clefting. The developmental role of Nat2 was investigated using transgenic Nat2 knockout/lacZ knockin (Nat2 (tm1Esim)) mice. The transgene was bred onto an A/J background and offspring were scored for developmental defects at weaning. After backcross generation eight, an ocular defect, ranging from cataract to microphthalmia and anophthalmia, was recorded among offspring of backcross and intercross pairs. Histologic analysis of cataract cases revealed a failure of the lens to separate from the cornea and plaques within the lens tissue. While Nat2 ( -/- ) mice have been described as overtly aphenotypic, the presence of a Nat2 null allele in one or both parents can result in ocular defects. These ocular phenotypes and their association with Nat2 genotype indicate that the Nat2 locus may be responsible for the previously described microphthalmic Cat4 phenotype and implicate the orthologous human NAT as a phenotypic modifier of microphthalmia and anophthalmia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487534     DOI: 10.1007/s00335-007-9010-z

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  45 in total

1.  The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida.

Authors:  Liselotte E Jensen; Katy Hoess; Alexander S Whitehead; Laura E Mitchell
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2005-07

2.  Triplication of 8p22-8p23 in a patient with features similar to Kabuki syndrome.

Authors:  Joseph T C Shieh; Louanne Hudgins; Athena M Cherry; Zhezhong Shen; H Eugene Hoyme
Journal:  Am J Med Genet A       Date:  2006-01-15       Impact factor: 2.802

3.  Methylenetetrahydrofolate reductase genetic polymorphisms in patients with cataract.

Authors:  Madeleine Zetterberg; Gunnar Tasa; Jonathan A Prince; Mona Palmér; Erkki Juronen; Siiri Veromann; Pait Teesalu; Jan-Olof Karlsson; Kaj Blennow; Henrik Zetterberg
Journal:  Am J Ophthalmol       Date:  2005-11       Impact factor: 5.258

4.  Arylamine N-acetyltransferase 2 expression in the developing heart.

Authors:  Larissa Wakefield; Valerie Cornish; Fiona Broackes-Carter; Edith Sim
Journal:  J Histochem Cytochem       Date:  2005-05       Impact factor: 2.479

Review 5.  Kabuki syndrome: a review.

Authors:  M P Adam; L Hudgins
Journal:  Clin Genet       Date:  2005-03       Impact factor: 4.438

6.  Modifications of human betaA1/betaA3-crystallins include S-methylation, glutathiolation, and truncation.

Authors:  Veniamin N Lapko; Ronald L Cerny; David L Smith; Jean B Smith
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

7.  Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism.

Authors:  A Ward; M J Summers; E Sim
Journal:  Biochem Pharmacol       Date:  1995-06-16       Impact factor: 5.858

8.  Asymmetric development of mitochondrial activity in rat embryos as a determinant of the defect patterns induced by exposure to hypoxia, hyperoxia, and redox cyclers in vitro.

Authors:  A G Fantel; R E Person; C Burroughs-Gleim; T H Shepard; M R Juchau; B Mackler
Journal:  Teratology       Date:  1991-09

Review 9.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.

Authors:  David W Hein
Journal:  Mutat Res       Date:  2002-09-30       Impact factor: 2.433

10.  Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms.

Authors:  Edward J Lammer; Gary M Shaw; David M Iovannisci; Janee Van Waes; Richard H Finnell
Journal:  Epidemiology       Date:  2004-03       Impact factor: 4.822

View more
  4 in total

1.  N-acetyltransferase 2 activity and folate levels.

Authors:  Wen Cao; Diana Strnatka; Charlene A McQueen; Robert J Hunter; Robert P Erickson
Journal:  Life Sci       Date:  2009-11-20       Impact factor: 5.037

2.  5-methyl-tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and effects of arylamine N-acetyltransferase-1 deletion.

Authors:  Katey L Witham; Neville J Butcher; Kim S Sugamori; Debbie Brenneman; Denis M Grant; Rodney F Minchin
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

3.  From arylamine N-acetyltransferase to folate-dependent acetyl CoA hydrolase: impact of folic acid on the activity of (HUMAN)NAT1 and its homologue (MOUSE)NAT2.

Authors:  Nicola Laurieri; Julien Dairou; James E Egleton; Lesley A Stanley; Angela J Russell; Jean-Marie Dupret; Edith Sim; Fernando Rodrigues-Lima
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

Review 4.  Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Authors:  E Sim; A Abuhammad; A Ryan
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.